These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19323963)

  • 1. Pharmacogenetics in diabetes.
    Pearson ER
    Curr Diab Rep; 2009 Apr; 9(2):172-81. PubMed ID: 19323963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes.
    Pearson ER
    Front Biosci (Landmark Ed); 2009 Jan; 14(11):4348-62. PubMed ID: 19273354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacogenetics of oral antidiabetic treatment].
    Tkáč I
    Vnitr Lek; 2016 Mar; 62(3):186-8. PubMed ID: 27180666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of glucose-lowering drug treatment: a systematic review.
    Bozkurt O; de Boer A; Grobbee DE; Heerdink ER; Burger H; Klungel OH
    Mol Diagn Ther; 2007; 11(5):291-302. PubMed ID: 17963417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.
    Glamočlija U; Jevrić-Čaušević A
    Acta Pharm; 2010 Dec; 60(4):387-406. PubMed ID: 21169132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics.
    Breitenstein MK; Simon G; Ryu E; Armasu SM; Weinshilboum RM; Wang L; Pathak J
    Stud Health Technol Inform; 2015; 210():914-8. PubMed ID: 25991289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.
    Staiger H; Schaeffeler E; Schwab M; Häring HU
    Rev Diabet Stud; 2015; 12(3-4):363-76. PubMed ID: 27111121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and personalized treatment of type 2 diabetes.
    Semiz S; Dujic T; Causevic A
    Biochem Med (Zagreb); 2013; 23(2):154-71. PubMed ID: 23894862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?
    Chan P; Shao L; Tomlinson B; Zhang Y; Liu ZM
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1149-1159. PubMed ID: 30375241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(1):54-8. PubMed ID: 23014256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?
    Pearson ER
    Clin Pharmacol Ther; 2019 Aug; 106(2):329-337. PubMed ID: 31012484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of oral antidiabetic treatment.
    Schroner Z; Javorsky M; Kozarova M; Tkac I
    Bratisl Lek Listy; 2011; 112(8):441-6. PubMed ID: 21863614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
    Florez JC
    Diabetologia; 2017 May; 60(5):800-807. PubMed ID: 28283684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of metformin: variability due to polymorphisms of organic cation transporters.
    Zolk O
    Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs.
    Xu H; Murray M; McLachlan AJ
    Curr Drug Metab; 2009 Jul; 10(6):643-58. PubMed ID: 19799532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.
    Garcin L; Mericq V; Fauret-Amsellem AL; Cave H; Polak M; Beltrand J
    Pediatr Diabetes; 2020 Sep; 21(6):932-941. PubMed ID: 32418263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of pharmacogenetics for individualizing drug treatment and for study design.
    Meisel C; Gerloff T; Kirchheiner J; Mrozikiewicz PM; Niewinski P; Brockmöller J; Roots I
    J Mol Med (Berl); 2003 Mar; 81(3):154-67. PubMed ID: 12682724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of oral antidiabetic drugs.
    Becker ML; Pearson ER; Tkáč I
    Int J Endocrinol; 2013; 2013():686315. PubMed ID: 24324494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular basis of oral hypoglycemic sulfonylurea action].
    Owecki M; Horst-Sikorska W; Sowiński J
    Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.